Stocksigma LogoStocksigma Logo

Metropolis Healthcare Reports Strong Q2FY27 Revenue and EBITDA Margin Growth

Metropolis Healthcare reported approximately 15% YoY consolidated revenue growth for Q2FY27, ending 30th Sep'26

Metropolis Healthcare Reports Strong Q2FY27 Revenue and EBITDA Margin Growth

Metropolis Healthcare Ltd 路 Others (Uncategorized) 路 05 Oct 2026, 11:42 pm

Metropolis Healthcare Reports Strong Q2FY27 Revenue and EBITDA Margin Growth Metropolis Healthcare reported approximately 15% YoY consolidated revenue growth for Q2FY27, ending 30th Sep'26. Topline growth was primarily driven by double-digit patient and test volume increases, supported by improved realizations and an enhanced product mix. TruHealth Wellness and Specialty emerged as the fastest-growing segments during the quarter. Additionally, EBITDA margins improved meaningfully on both a YoY and QoQ basis, bolstered by operating leverage and efficiency gains. Detailed financial results remain subject to auditor review.

Original exchange filing (PDF)

More announcements from Metropolis Healthcare Ltd

All Metropolis Healthcare Ltd announcements